Physician profile
Jerry A Horowitz
NPI 1225065311
$876.25
in general payments reported to CMS, 2019-2025
15 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $152 · 2022: $59.26 · 2023: $13.31 · 2024: $13.41 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $95.33 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $95.33 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $197.65 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $137.60 | 2019-2025 | Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $90.97 | 2019-2025 | Farxiga |
| Amgen INC. | $79.34 | 2019-2022 | |
| Pfizer INC. | $77.60 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $57.13 | 2019-2022 | |
| Amarin Pharma, INC. | $45.13 | 2020 | |
| Merck Sharp & Dohme LLC | $38.17 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $30.60 | 2019 | |
| Sunovion Pharmaceuticals INC. | $29.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.66 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.12 | 2019-2020 | |
| Glaxosmithkline, LLC. | $14.46 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.58 | 2019 | |
| Abbvie INC. | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Horowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.